Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright
Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was ...
Immunovant price target lowered to $33 from $38 at BofA
BofA lowered the firm’s price target on Immunovant (IMVT) to $33 from $38 and keeps a Buy rating on the shares after yesterday’s topline data ...
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. Read more about ZLAB stock here.
Immunovant data positive for Biohaven, says Deutsche Bank
Deutsche Bank says Biohaven’s (BHVN) competitor Immunovant (IMVT) reported topline data for FcRn antibody batoclimab in myasthenia gravis and ...
PipelineReview.com16h
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, NY, USA I March 19, 2025 I Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with ...
Researchers find a hint at how to delay Alzheimer’s symptoms. Now they have to prove it
The new findings center on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight ...
What is William Blair’s Estimate for argenx Q1 Earnings?
Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of argenx in a research note issued on ...
William Blair Comments on argenx’s Q4 Earnings (NASDAQ:ARGX)
Equities researchers at William Blair issued their Q4 2026 earnings estimates for argenx in a report released on Monday, ...